Why did an FDA panel recently decisively reject MDMA for medical use despite some supportive scientific studies? Join us on the TDR podcast as we grapple with this critical and controversial topic alongside our distinguished guest, Kevin Sabet. In this episode, we unpack the intricate history and ambitions of MAPS, the organization led by Rick Doblin, which transformed into the for-profit Lycos Therapeutics. Kevin offers his expertise on the mixed results from rigorous studies submitted to the FDA and the factors behind the panel's overwhelming vote against MDMA for treating PTSD. This discussion sheds light on the broader implications for psychedelic therapies and FDA regulations.
We also delve into the media frenzy and the optimistic anticipation within the psychedelics advocacy community leading up to the panel's decision. Despite the buzz and support from certain quarters, the committee's vote of 10 to 1 against MDMA underscores the complexities and risks associated with approving psychedelics for medical use. Get ready for a comprehensive analysis of this pivotal decision and its potential impact on the future landscape of PTSD treatments. Tune in for valuable insights on what lies ahead for MDMA in therapeutic settings and the FDA's ultimate stance.
Follow the work of SAM and FDPS below:
https://learnaboutsam.org/
https://gooddrugpolicy.org/
https://thedrugreport.org/
On X:
https://twitter.com/learnaboutsam
https://twitter.com/GoodDrugPolicy
https://twitter.com/KevinSabet
https://twitter.com/LukeNiforatos
On Facebook: https://www.facebook.com/learnaboutsam
